SLC5A2 and diabetic kidney disease: Given the important yet incomplete renoprotective roles of RAAS inhibitors in diabetic nephropathy (Bilous et al., 2009; Lewis et al., 1993; Lewis et al., 2001; Mauer et al., 2009), another question to consider is whether SGLT2 inhibition has additive renoprotective effects to RAAS inhibition.